Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAX-40279-01 + Azacitidine in MDS and R/R AML
NCT05061147Phase 2Unknown
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nefextinib in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Guangzhou Zaiji Medical Technology. Status: unknown.
02
Drugs
nefextinib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05061147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061147.